GENEVA, June 1, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today representatives from the Company will be participating in the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.
Selexis has interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis' SURE technology platform allows for faster and more reliable cell line development with higher expression levels which can be applied to a wide range of areas such as bio-manufacturing, drug discovery, diagnostics and therapeutics.
Representatives available to discuss Selexis' capabilities include: Dr. Igor Fisch, CEO; Andrew Sandford, VP Business Development and Licensing; Dr. Armelle Gaussin, Chief Technology Officer; and Dr. Denise Huber, Director of Business Development. Companies or individuals attending BIO 2011 can schedule meetings with Selexis by visiting (registration required): oneononepartnering.bio.org/BusinessForum2011/Login.aspx.
Selexis Partnering Schedule:
Monday, June 27 Business Forum - 12:00 PM - 5:00 PM
Tuesday, June 28 Business Forum - 7:00 AM – 6:00 PM
Wednesday, June 29 Business Forum - 7:00 AM – 6:00 PM
Thursday, June 30 Business Forum - 7:00 AM – 6:00 PM
For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #1906 located in Hall A – Discovery Zone (e.mybio
|SOURCE Selexis SA|
Copyright©2010 PR Newswire.
All rights reserved